• Product
• Butterfly effect caused by brand name purchase
• by Kim JiEun Mar 23, 2022 05:50am

• Policy
• Rozlytrek & Vitrakvi are likely to be listed in April
• by Lee, Tak-Sun Mar 22, 2022 05:54am

• Company
• Seqirus 'will introduce the first adjuvanted flu vaccine'
• by Mar 22, 2022 05:53am

• Company
• GSK’s immuno-oncology drug Jemperli applies for approval
• by Eo, Yun-Ho Mar 22, 2022 05:53am

• Company
• Esophageal cancer, added to indication of Opdivo·Keytruda
• by Eo, Yun-Ho Mar 22, 2022 05:53am

• Company
• Celltrion was fined 13.9 billion won
• by Kim, Jin-Gu Mar 22, 2022 05:53am

• Company
• Concerns over fungal infection due to COVID-19
• by Eo, Yun-Ho Mar 21, 2022 05:56am

• Product
• Paxlovid shortage to be resolved with Molnupiravir approval?
• by Jung, Heung-Jun Mar 21, 2022 05:55am

• Company
• 5 companies challenge breast cancer drug Ibrance’s patent
• by Kim, Jin-Gu Mar 21, 2022 05:55am

• Policy
• Actemra is likely to be reimbursed for managing CRS
• by Kim, Jung-Ju Mar 21, 2022 05:55am